# Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events

> **NCT07734753** · — · COMPLETED · sponsor: **Sanofi** · enrollment: 4006 (actual)

## Conditions studied

- Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Comparator: No PCSK9i Therapy (monoclonal antibodies or small interfering RNA agents)

## Key facts

- **NCT ID:** NCT07734753
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-15
- **Primary completion:** 2026-05-15
- **Final completion:** 2026-08-15
- **Target enrollment:** 4006 (ACTUAL)
- **Last updated:** 2026-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07734753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07734753, "Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07734753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*